For cancer patients, including those with recurrent ovarian cancer, an important cause of morbidity is malignant ascites. Researchers here evaluated the activity of intraperitoneal injections of low-dose bevacizumab in delaying re-accumulation of malignant ascites in women with chemotherapy-resistant epithelial ovarian … Read more
Incidence of MDS/AML under 1%, but further investigation warranted as indications broaden
By Leah Lawrence
Although rare, poly-ADP ribose polymerase (PARP) inhibitors were associated with an increased risk for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), and occurred even … Read more
These results suggest the need for future studies to examine scalable interventions to improve fatigue in women with gynecologic cancers.
By Hannah Slater
A 1-year longitudinal study published in Cancer suggested that almost half of women with gynecologic cancers had
By Kristen Monaco
Researchers advocate for increased hormone therapy for high-risk women.
Bone health suffered in women with a BRCA mutation who underwent preventive oophorectomy, Canadian researchers reported.
Premenopausal women with the BRCA1 or BRCA2 mutation experienced a significant decline … Read more
Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects.
Luckily, doctors have a variety of ways to relieve or prevent these discomforts.… Read more
By Dr. Leslie Boyd
Ovarian cancer produces the type of tumor that oncologists like to call “chemo-sensitive”—which is pretty good news for anyone diagnosed. Ovarian cancer cells have been shown to respond well to a combination of chemo drugs, which … Read more
By Kristie L. Kahl
Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis… Read more
By Ian Ingram
In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.
Compared with placebo, … Read more
By Will Pass
Women who have survived epithelial ovarian cancer (EOC) more often report severe long-term fatigue than healthy women, according to a case-control study involving more than 600 individuals.
Ovarian cancer survivors had a higher rate of sleep disturbance, … Read more
by Madeline Marr
The use of niraparib in women receiving treatment for platinum-sensitive recurrent ovarian cancer did not adversely affect quality of life (QoL), according to a study published in The Lancet Oncology.
An international team of researchers led … Read more
The FDA granted expanded clearance to the Paxman Scalp Cooling System, allowing the device to be used by patients with any type of solid tumor.
The Paxman Scalp Cooling System (Paxman) — designed to reduce hair loss among patients who … Read more
Data from a new survey show that as many as 80% of oncologists have discussed medical marijuana use with their patients. According to the authors, this is the first nationally representative survey to examine oncologists’ practices and beliefs on the … Read more